- Patients
- Clinical Research
- Clinical trials
- KEYNOTE 676
2023-05-24T00:00:00.000+08:00
Ongoing
KEYNOTE 676
KEYNOTE 676
Bladder cancer
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus CalmetteGuerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676)
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus CalmetteGuerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676)
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Bladder cancer
Study Phase
III
Trial Identifiers
NCT03711032
GenesisCare Location(s)
GenesisCare North Shore
:::
Principal Investigator(s)